行情

BIIB

BIIB

生物基因
NASDAQ

实时行情|Nasdaq Last Sale

292.23
-4.97
-1.67%
盘后: 292.00 -0.23 -0.08% 18:23 12/11 EST
开盘
296.82
昨收
297.20
最高
299.29
最低
292.00
成交量
131.40万
成交额
--
52周最高
344.00
52周最低
215.78
市值
539.01亿
市盈率(TTM)
10.35
分时
5日
1月
3月
1年
5年

分析师评级

32位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BIIB 新闻

  • Big biotech deals: 5 trades
  • CNBC.com.2天前
  • JP Morgan says it may be time to look at stocks abroad
  • CNBC.com.2天前
  • Why Shares of PDL BioPharma Are Soaring Today
  • MotleyFool.com.2天前
  • J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH
  • Zacks.2天前

更多

所属板块

制药
+0.17%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

BIIB 简况

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
展开

Webull提供Biogen Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。